For the quarter ending 2026-03-31, AIM made $22K in revenue. -$3,023K in net income. Net profit margin of -13740.91%.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 22 | 26 | 25 | 42.5 |
| Production costs | 4 | 68 | 10 | 7* |
| Research and development | 482 | 607 | 1,174 | 2,324* |
| General and administrative | 1,762 | 1,798 | 1,487 | 7,099* |
| Issuance cost | - | 433 | - | - |
| Total costs and expenses | 2,248 | 2,473 | 2,671 | 9,429.5 |
| Loss on issuance of warrants | - | -3,977 | 0 | - |
| Operating loss | -2,226 | -2,447 | -2,646 | -9,387* |
| (loss) gain on investments | -1 | -1 | -9 | -375* |
| Interest and other income | 8 | 3,052 | 10 | 245* |
| Interest expense and other finance costs | 304 | 148 | 149 | 14* |
| (gain) on warrant issuance | - | - | - | 916* |
| Loss on change in fair value of warrant liability | 468 | -670 | - | - |
| (loss) gain from sale of income tax operating losses | - | - | - | 401* |
| Loss on issuance of warrants | 32 | - | - | - |
| Net loss | -3,023 | -3,284 | -2,794 | -9,016 |
| Basic EPS | -0.69 | 1.57 | -3.68 | -0.157 |
| Diluted EPS | -0.69 | 1.57 | -3.68 | -0.157 |
| Basic Average Shares | 4,351,449 | 2,093,446 | 759,289 | 57,536,117 |
| Diluted Average Shares | 4,351,449 | 2,093,446 | 759,289 | 57,536,117 |
AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. (AIM)